The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration

The next therapeutic frontier)

Adam L. Boxer, Michael Gold, Edward Huey, William T. Hu, Howard Rosen, Joel Kramer, Fen Biao Gao, Edward A. Burton, Tiffany Chow, Aimee Kao, Blair R. Leavitt, Bruce Lamb, Megan Grether, David Knopman, Nigel J. Cairns, Ian R. Mackenzie, Laura Mitic, Erik D. Roberson, Daniel Van Kammen, Marc Cantillon & 23 others Kathleen Zahs, George Jackson, Stephen Salloway, John Morris, Gary Tong, Howard Feldman, Howard Fillit, Susan Dickinson, Zaven S. Khachaturian, Margaret Sutherland, Susan Abushakra, Joseph Lewcock, Robert Farese, Robert O. Kenet, Frank Laferla, Steve Perrin, Steve Whitaker, Lawrence Honig, Marsel M. Mesulam, Brad Boeve, Murray Grossman, Bruce L. Miller, Jeffrey L. Cummings

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Frontotemporal degeneration (FTD) encompasses a spectrum of related neurodegenerative disorders with behavioral, language, and motor phenotypes for which there are currently no effective therapies. This is the second of two articles that summarize the presentations and discussions that occurred at two symposia in 2011 sponsored by the Frontotemporal Degeneration Treatment Study Group, a collaborative group of academic and industry researchers that is devoted to developing treatments for FTD. This article discusses the current status of FTD clinical research that is relevant to the conduct of clinical trials, and why FTD research may be an attractive pathway for developing therapies for neurodegenerative disorders. The clinical and molecular features of FTD, including rapid disease progression and relatively pure molecular pathology, suggest that there are advantages to developing drugs for FTD as compared with other dementias. FTD qualifies as orphan indication, providing additional advantages for drug development. Two recent sets of consensus diagnostic criteria will facilitate the identification of patients with FTD, and a variety of neuropsychological, functional, and behavioral scales have been shown to be sensitive to disease progression. Moreover, quantitative neuroimaging measurements demonstrate progressive brain atrophy in FTD at rates that may surpass Alzheimer's disease. Finally, the similarities between FTD and other neurodegenerative diseases with drug development efforts already underway suggest that FTD researchers will be able to draw on this experience to create a road map for FTD drug development. We conclude that FTD research has reached sufficient maturity to pursue clinical development of specific FTD therapies.

Original languageEnglish (US)
Pages (from-to)189-198
Number of pages10
JournalAlzheimer's and Dementia
Volume9
Issue number2
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Neurodegenerative Diseases
Pharmaceutical Preparations
Disease Progression
Research
Research Personnel
Therapeutics
Orphaned Children
Molecular Pathology
Neuroimaging
Atrophy
Dementia
Consensus
Industry
Alzheimer Disease
Language
Clinical Trials
Phenotype
Brain

Keywords

  • AD
  • Alzheimer's disease
  • Biomarker
  • Clinical trial
  • Corticobasal degeneration
  • Drug development
  • Frontotemporal degeneration
  • FTD
  • Progressive supranuclear palsy
  • Treatment

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration : The next therapeutic frontier). / Boxer, Adam L.; Gold, Michael; Huey, Edward; Hu, William T.; Rosen, Howard; Kramer, Joel; Gao, Fen Biao; Burton, Edward A.; Chow, Tiffany; Kao, Aimee; Leavitt, Blair R.; Lamb, Bruce; Grether, Megan; Knopman, David; Cairns, Nigel J.; Mackenzie, Ian R.; Mitic, Laura; Roberson, Erik D.; Van Kammen, Daniel; Cantillon, Marc; Zahs, Kathleen; Jackson, George; Salloway, Stephen; Morris, John; Tong, Gary; Feldman, Howard; Fillit, Howard; Dickinson, Susan; Khachaturian, Zaven S.; Sutherland, Margaret; Abushakra, Susan; Lewcock, Joseph; Farese, Robert; Kenet, Robert O.; Laferla, Frank; Perrin, Steve; Whitaker, Steve; Honig, Lawrence; Mesulam, Marsel M.; Boeve, Brad; Grossman, Murray; Miller, Bruce L.; Cummings, Jeffrey L.

In: Alzheimer's and Dementia, Vol. 9, No. 2, 03.2013, p. 189-198.

Research output: Contribution to journalArticle

Boxer, AL, Gold, M, Huey, E, Hu, WT, Rosen, H, Kramer, J, Gao, FB, Burton, EA, Chow, T, Kao, A, Leavitt, BR, Lamb, B, Grether, M, Knopman, D, Cairns, NJ, Mackenzie, IR, Mitic, L, Roberson, ED, Van Kammen, D, Cantillon, M, Zahs, K, Jackson, G, Salloway, S, Morris, J, Tong, G, Feldman, H, Fillit, H, Dickinson, S, Khachaturian, ZS, Sutherland, M, Abushakra, S, Lewcock, J, Farese, R, Kenet, RO, Laferla, F, Perrin, S, Whitaker, S, Honig, L, Mesulam, MM, Boeve, B, Grossman, M, Miller, BL & Cummings, JL 2013, 'The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)', Alzheimer's and Dementia, vol. 9, no. 2, pp. 189-198. https://doi.org/10.1016/j.jalz.2012.03.003
Boxer, Adam L. ; Gold, Michael ; Huey, Edward ; Hu, William T. ; Rosen, Howard ; Kramer, Joel ; Gao, Fen Biao ; Burton, Edward A. ; Chow, Tiffany ; Kao, Aimee ; Leavitt, Blair R. ; Lamb, Bruce ; Grether, Megan ; Knopman, David ; Cairns, Nigel J. ; Mackenzie, Ian R. ; Mitic, Laura ; Roberson, Erik D. ; Van Kammen, Daniel ; Cantillon, Marc ; Zahs, Kathleen ; Jackson, George ; Salloway, Stephen ; Morris, John ; Tong, Gary ; Feldman, Howard ; Fillit, Howard ; Dickinson, Susan ; Khachaturian, Zaven S. ; Sutherland, Margaret ; Abushakra, Susan ; Lewcock, Joseph ; Farese, Robert ; Kenet, Robert O. ; Laferla, Frank ; Perrin, Steve ; Whitaker, Steve ; Honig, Lawrence ; Mesulam, Marsel M. ; Boeve, Brad ; Grossman, Murray ; Miller, Bruce L. ; Cummings, Jeffrey L. / The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration : The next therapeutic frontier). In: Alzheimer's and Dementia. 2013 ; Vol. 9, No. 2. pp. 189-198.
@article{3c6334ae49034886a14563bf2e0efa2f,
title = "The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)",
abstract = "Frontotemporal degeneration (FTD) encompasses a spectrum of related neurodegenerative disorders with behavioral, language, and motor phenotypes for which there are currently no effective therapies. This is the second of two articles that summarize the presentations and discussions that occurred at two symposia in 2011 sponsored by the Frontotemporal Degeneration Treatment Study Group, a collaborative group of academic and industry researchers that is devoted to developing treatments for FTD. This article discusses the current status of FTD clinical research that is relevant to the conduct of clinical trials, and why FTD research may be an attractive pathway for developing therapies for neurodegenerative disorders. The clinical and molecular features of FTD, including rapid disease progression and relatively pure molecular pathology, suggest that there are advantages to developing drugs for FTD as compared with other dementias. FTD qualifies as orphan indication, providing additional advantages for drug development. Two recent sets of consensus diagnostic criteria will facilitate the identification of patients with FTD, and a variety of neuropsychological, functional, and behavioral scales have been shown to be sensitive to disease progression. Moreover, quantitative neuroimaging measurements demonstrate progressive brain atrophy in FTD at rates that may surpass Alzheimer's disease. Finally, the similarities between FTD and other neurodegenerative diseases with drug development efforts already underway suggest that FTD researchers will be able to draw on this experience to create a road map for FTD drug development. We conclude that FTD research has reached sufficient maturity to pursue clinical development of specific FTD therapies.",
keywords = "AD, Alzheimer's disease, Biomarker, Clinical trial, Corticobasal degeneration, Drug development, Frontotemporal degeneration, FTD, Progressive supranuclear palsy, Treatment",
author = "Boxer, {Adam L.} and Michael Gold and Edward Huey and Hu, {William T.} and Howard Rosen and Joel Kramer and Gao, {Fen Biao} and Burton, {Edward A.} and Tiffany Chow and Aimee Kao and Leavitt, {Blair R.} and Bruce Lamb and Megan Grether and David Knopman and Cairns, {Nigel J.} and Mackenzie, {Ian R.} and Laura Mitic and Roberson, {Erik D.} and {Van Kammen}, Daniel and Marc Cantillon and Kathleen Zahs and George Jackson and Stephen Salloway and John Morris and Gary Tong and Howard Feldman and Howard Fillit and Susan Dickinson and Khachaturian, {Zaven S.} and Margaret Sutherland and Susan Abushakra and Joseph Lewcock and Robert Farese and Kenet, {Robert O.} and Frank Laferla and Steve Perrin and Steve Whitaker and Lawrence Honig and Mesulam, {Marsel M.} and Brad Boeve and Murray Grossman and Miller, {Bruce L.} and Cummings, {Jeffrey L.}",
year = "2013",
month = "3",
doi = "10.1016/j.jalz.2012.03.003",
language = "English (US)",
volume = "9",
pages = "189--198",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration

T2 - The next therapeutic frontier)

AU - Boxer, Adam L.

AU - Gold, Michael

AU - Huey, Edward

AU - Hu, William T.

AU - Rosen, Howard

AU - Kramer, Joel

AU - Gao, Fen Biao

AU - Burton, Edward A.

AU - Chow, Tiffany

AU - Kao, Aimee

AU - Leavitt, Blair R.

AU - Lamb, Bruce

AU - Grether, Megan

AU - Knopman, David

AU - Cairns, Nigel J.

AU - Mackenzie, Ian R.

AU - Mitic, Laura

AU - Roberson, Erik D.

AU - Van Kammen, Daniel

AU - Cantillon, Marc

AU - Zahs, Kathleen

AU - Jackson, George

AU - Salloway, Stephen

AU - Morris, John

AU - Tong, Gary

AU - Feldman, Howard

AU - Fillit, Howard

AU - Dickinson, Susan

AU - Khachaturian, Zaven S.

AU - Sutherland, Margaret

AU - Abushakra, Susan

AU - Lewcock, Joseph

AU - Farese, Robert

AU - Kenet, Robert O.

AU - Laferla, Frank

AU - Perrin, Steve

AU - Whitaker, Steve

AU - Honig, Lawrence

AU - Mesulam, Marsel M.

AU - Boeve, Brad

AU - Grossman, Murray

AU - Miller, Bruce L.

AU - Cummings, Jeffrey L.

PY - 2013/3

Y1 - 2013/3

N2 - Frontotemporal degeneration (FTD) encompasses a spectrum of related neurodegenerative disorders with behavioral, language, and motor phenotypes for which there are currently no effective therapies. This is the second of two articles that summarize the presentations and discussions that occurred at two symposia in 2011 sponsored by the Frontotemporal Degeneration Treatment Study Group, a collaborative group of academic and industry researchers that is devoted to developing treatments for FTD. This article discusses the current status of FTD clinical research that is relevant to the conduct of clinical trials, and why FTD research may be an attractive pathway for developing therapies for neurodegenerative disorders. The clinical and molecular features of FTD, including rapid disease progression and relatively pure molecular pathology, suggest that there are advantages to developing drugs for FTD as compared with other dementias. FTD qualifies as orphan indication, providing additional advantages for drug development. Two recent sets of consensus diagnostic criteria will facilitate the identification of patients with FTD, and a variety of neuropsychological, functional, and behavioral scales have been shown to be sensitive to disease progression. Moreover, quantitative neuroimaging measurements demonstrate progressive brain atrophy in FTD at rates that may surpass Alzheimer's disease. Finally, the similarities between FTD and other neurodegenerative diseases with drug development efforts already underway suggest that FTD researchers will be able to draw on this experience to create a road map for FTD drug development. We conclude that FTD research has reached sufficient maturity to pursue clinical development of specific FTD therapies.

AB - Frontotemporal degeneration (FTD) encompasses a spectrum of related neurodegenerative disorders with behavioral, language, and motor phenotypes for which there are currently no effective therapies. This is the second of two articles that summarize the presentations and discussions that occurred at two symposia in 2011 sponsored by the Frontotemporal Degeneration Treatment Study Group, a collaborative group of academic and industry researchers that is devoted to developing treatments for FTD. This article discusses the current status of FTD clinical research that is relevant to the conduct of clinical trials, and why FTD research may be an attractive pathway for developing therapies for neurodegenerative disorders. The clinical and molecular features of FTD, including rapid disease progression and relatively pure molecular pathology, suggest that there are advantages to developing drugs for FTD as compared with other dementias. FTD qualifies as orphan indication, providing additional advantages for drug development. Two recent sets of consensus diagnostic criteria will facilitate the identification of patients with FTD, and a variety of neuropsychological, functional, and behavioral scales have been shown to be sensitive to disease progression. Moreover, quantitative neuroimaging measurements demonstrate progressive brain atrophy in FTD at rates that may surpass Alzheimer's disease. Finally, the similarities between FTD and other neurodegenerative diseases with drug development efforts already underway suggest that FTD researchers will be able to draw on this experience to create a road map for FTD drug development. We conclude that FTD research has reached sufficient maturity to pursue clinical development of specific FTD therapies.

KW - AD

KW - Alzheimer's disease

KW - Biomarker

KW - Clinical trial

KW - Corticobasal degeneration

KW - Drug development

KW - Frontotemporal degeneration

KW - FTD

KW - Progressive supranuclear palsy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84875371839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875371839&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2012.03.003

DO - 10.1016/j.jalz.2012.03.003

M3 - Article

VL - 9

SP - 189

EP - 198

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 2

ER -